A Phase III Study of MG-K10 in Adolescents With Moderate-to-Severe Atopic Dermatitis

Starting soon · Phase 3 · Has a placebo group

Conditions studied: Dermatitis, Atopic

In brief

This is a randomized, double-blind, placebo-controlled, parallel group study to confirm the efficacy and safety of MG-K10 monotherapy in adolescents with moderate-to-severe atopic dermatitis (AD)

Key facts

Study ID

NCT07540442

Run by

Shanghai Mabgeek Biotech.Co.Ltd

People needed

180

Starts

2026-04-17

Expected to finish

2027-11-09

Last updated by the study team

2026-04-20

Who can join

Age: 12 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of Atopic Dermatitis (AD) per American Academy of Dermatology (2014) criteria for ≥6 months;
• Eczema Area and Severity Index (EASI) ≥16;
• Investigator's Global Assessment (IGA) ≥3;
• Body Surface Area (BSA) involvement ≥10%;
• Peak Pruritus Numerical Rating Scale (NRS) weekly average ≥4;
• Inadequate response to topical treatments within 6 months or medically inadvisable to use topical treatments.

You may not qualify if…

• Inability to tolerate venipuncture, or a history of needle phobia or hematophobia;
• Inability to receive subcutaneous injections, such as patients currently receiving anticoagulant therapy, or those with known bleeding disorders or idiopathic thrombocytopenic purpura;
• Presence of ophthalmic diseases judged by the investigator to be unsuitable for inclusion;
• Concurrent serious diseases including, but not limited to, cardiovascular, metabolic, or neurological diseases, which, in the opinion of the investigator, render the subject unsuitable for immunosuppressive therapy;
• History of parasitic infection within 6 months prior to screening;
• Planned major surgery during the study period;
• Prior or concomitant treatments meeting any of the following:
• Use of biologics within 10 weeks prior to randomization or within 5 half-lives (whichever is longer)
• Use of targeted inhibitors (e.g., JAK inhibitors), systemic glucocorticoids, cyclosporine, or other immunosuppressants (e.g., methotrexate, MMF, azathioprine), phosphodiesterase-4 (PDE4) inhibitors, phototherapy (UV), or systemic Chinese herbal medicine for AD within 4 weeks prior to randomization
• Use of topical treatments for AD (e.g., topical glucocorticoids, topical calcineurin inhibitors, antibiotic combination creams, or topical Chinese herbal medicine) within 2 weeks prior to randomization
• Receipt of live or attenuated vaccines within 3 months prior to randomization or plans to receive such vaccines during the study
• Participation in other clinical trials within 3 months or 5 half-lives (whichever is longer) prior to randomization, or plans to participate in other clinical trials during the study period
• Systemic anti-infective therapy (oral or intravenous antibacterial, antiviral, or antifungal) within 4 weeks prior to randomization, or current acute or subacute infection indicated by symptoms, signs, or laboratory abnormalities
• History of alcohol or drug abuse within 6 months prior to screening; Known allergy or intolerance to any component of the investigational product.
• Other conditions that, in the opinion of the investigator, make the subject unsuitable for participation in the study.

Where it is running

• The First Hospital Of China Medical University — Shenyang, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.